Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07422480

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (ELRiSE MDS)

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

Sponsor: Takeda

Conditions Anemia Myelodysplastic Syndrome

Interventions Elritercept Epoetin Alfa

Updated 2 times since 2026 Last updated: Mar 5, 2026 Started: Apr 1, 2026 Primary completion: Apr 30, 2029 Completion: Oct 1, 2033

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Anemia and Myelodysplastic Syndrome and is currently actively recruiting participants. Takeda leads this study, which shows 2 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Feb 2026 — Mar 2026 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Alexandroupoli, Greece , Amagasaki, Japan , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Athens, Greece , Atlanta, United States , Ban Phaeo, Thailand , Bangkok, Thailand , Barcelona, Spain and 123 more locations